$20M Upfront, $1.4B Milestones: Nuvectis Pharma Secures Ex-China Rights to NXP100 & NXP200
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (4.4× avg).
Summary
Nuvectis Pharma has secured an exclusive ex-China license for two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group. The agreement includes a $20 million upfront payment and potential development, regulatory, and commercial milestones totaling up to $1.4 billion. This follows an 8-K filing today and a GlobeNewswire report yesterday detailing the same licensing agreement. The $20 million upfront payment is a material investment for the company, which reported a $6.05 million net loss and $6.51 million cash burn in Q1 2026. The deal significantly expands Nuvectis's pipeline in oncology and immunology, offering substantial long-term revenue potential. The agreement is subject to financing conditions to fund development, which will be a key factor to watch.
At the time of this announcement, NVCT was trading at $16.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $438.5M. The 52-week trading range was $5.55 to $16.64. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.